{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:38:46Z","timestamp":1787841526275,"version":"build-2784847793"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Due to the pathogenic role of opportunistic fungi in immunodeficiency patients, many efforts have been made for developing effective treatment strategies to augment current practice standards. Nystatin, as one of the treatment candidates, is characterized by antifungal effects. In this study, we tried to use liposomal formulation as a nystatin carrier to increase its antifungal efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      A total of 87 positive culture samples of yeast agents were applied to the study. Yeast species were identified by culturing on CHROMagar medium (HiMEDIA), culturing on NigerSide agar medium, and Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP). Characterization of nanoparticles was examined by the size, zeta potential (ZP), scanning electron microscope (SEM), drug loading, and drug release rate. The standard method of broth microdilution according to CLSI M27-A and the quality control standard of\n                      <jats:italic toggle=\"yes\">Candida<\/jats:italic>\n                      <jats:italic toggle=\"yes\">parapsilosis<\/jats:italic>\n                      ATCC 22019 were used to evaluate the minimum inhibitory concentration (MIC) of nystatin and nystatin nanoliposomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The particle size for liposomes containing nystatin was 100.8 \u00b1 17.3 nm. Moreover, the ZP for liposomal formulation of nystatin was 21.14 \u00b1 0.92 \u2013mV. The formulation of nystatin in nanoparticles markedly increased the susceptibility of\n                      <jats:italic toggle=\"yes\">Candida<\/jats:italic>\n                      species to nystatin at lower doses, which was statistically significant compared to free nystatin (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2264 0.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      Our results showed that liposomal formulation improves the efficiency of nystatin against\n                      <jats:italic toggle=\"yes\">albicans<\/jats:italic>\n                      species. This formulation can be used to develop new antifungal agents to improve the delivery and absorption of hydrophobic drugs.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/abr.abr_65_23","type":"journal-article","created":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T08:10:25Z","timestamp":1722240625000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Nystatin Encapsulated Nanoliposomes: Potential Anti-infective against Candida Spp. Isolated from Candidiasis Patients"],"prefix":"10.4103","volume":"13","author":[{"given":"Mehrdad","family":"Asadi","sequence":"first","affiliation":[{"name":"Department of Medical Laboratory Sciences and Microbiology, Faculty of Medical Sciences, Tabriz Medical Sciences, Islamic Azad University, Tabriz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attabak","family":"Toofani-Milani","sequence":"additional","affiliation":[{"name":"Department of Medical Laboratory Sciences and Microbiology, Faculty of Medical Sciences, Tabriz Medical Sciences, Islamic Azad University, Tabriz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katayoun","family":"Bahman Soufiani","sequence":"additional","affiliation":[{"name":"Department of Medical Laboratory Sciences and Microbiology, Faculty of Medical Sciences, Tabriz Medical Sciences, Islamic Azad University, Tabriz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,7]]},"reference":[{"key":"R1-20240830","doi-asserted-by":"crossref","first-page":"111643","DOI":"10.1016\/j.envres.2021.111643","article-title":"Mucormycosis: An opportunistic pathogen during COVID-19","volume":"201","author":"Mahalaxmi","year":"2021","journal-title":"Environ Res"},{"key":"R2-20240830","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3390\/microorganisms8020154","article-title":"Candida albicans antifungal resistance and tolerance in bloodstream infections: The triad yeast-host-antifungal","volume":"8","author":"Costa-de-Oliveira","year":"2020","journal-title":"Microorganisms"},{"key":"R4-20240830","first-page":"33","article-title":"Invasive candidiasis: Epidemiology and risk factors","author":"Cort\u00e9s","year":"2018","journal-title":"Fungal Infection"},{"key":"R5-20240830","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1574-6976.2011.00278.x","article-title":"Candida glabrata, Candida parapsilosis and Candida tropicalis: Biology, epidemiology, pathogenicity and antifungal resistance","volume":"36","author":"Silva","year":"2012","journal-title":"FEMS Microbiol Rev"},{"key":"R6-20240830","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1128\/AAC.46.6.1704-1713.2002","article-title":"Resistance mechanisms in clinical isolates of Candida albicans","volume":"46","author":"White","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"R7-20240830","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1086\/513664","article-title":"Oropharyngeal candidiasis in patients with AIDS: Randomized comparison of fluconazole versus nystatin oral suspensions","volume":"24","author":"Pons","year":"1997","journal-title":"Clin Infect Dis"},{"key":"R8-20240830","first-page":"48","article-title":"Antifungal agents: Polyene, azole, antimetabolite, other and future agents","volume":"5","author":"Ali Malayeri","year":"2018","journal-title":"J Basic Res Med Sci"},{"key":"R9-20240830","first-page":"63","article-title":"Synthesis, characterization and antifungal activity of coated silver nanoparticles-nystatin and coated silver nanoparticles-clotrimazol","volume":"23","author":"Alheety","year":"2018","journal-title":"Tikrit J Pure Sci"},{"key":"R10-20240830","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jddst.2018.12.014","article-title":"A promising nystatin nanocapsular hydrogel as an antifungal polymeric carrier for the treatment of topical candidiasis","volume":"49","author":"AbouSamra","year":"2019","journal-title":"J Drug Deliv Sci Technol"},{"key":"R11-20240830","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2147\/IDR.S226154","article-title":"Antifungal activity of ZnO nanoparticles and nystatin and downregulation of SAP1-3 genes expression in fluconazole-resistant Candida albicans isolates from vulvovaginal candidiasis","volume":"13","author":"Hosseini","year":"2020","journal-title":"Infect Drug Resist"},{"key":"R12-20240830","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00210-019-01692-5","article-title":"Sensitization of MDA-MBA231 breast cancer cell to docetaxel by myricetin loaded into biocompatible lipid nanoparticles via sub-G1 cell cycle arrest mechanism","volume":"393","author":"Maroufi","year":"2020","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"R13-20240830","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1007\/s00210-020-01942-x","article-title":"Formulation of Stattic as STAT3 inhibitor in nanostructured lipid carriers (NLCs) enhances efficacy of doxorubicin in melanoma cancer cells","volume":"393","author":"Mohammadian","year":"2020","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"R14-20240830","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijpharm.2004.02.032","article-title":"Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery","volume":"278","author":"Souto","year":"2004","journal-title":"Int J Pharm"},{"key":"R15-20240830","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/02652040500162436","article-title":"SLN and NLC for topical delivery of ketoconazole","volume":"22","author":"Souto","year":"2005","journal-title":"J Microencapsul"},{"key":"R16-20240830","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.colsurfb.2013.05.041","article-title":"Miconazole-loaded nanostructured lipid carriers (NLC) for local delivery to the oral mucosa: Improving antifungal activity","volume":"111","author":"Mendes","year":"2013","journal-title":"Colloids Surf B Biointerfaces"},{"key":"R17-20240830","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.chemphyslip.2012.01.006","article-title":"Development, characterization and in vivo assessment of effective lipidic nanoparticles for dermal delivery of fluconazole against cutaneous candidiasis","volume":"165","author":"Gupta","year":"2012","journal-title":"Chem Phys Lipids"},{"key":"R18-20240830","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1080\/01635581.2019.1650191","article-title":"Application of \u0251-tocotrienol-loaded biocompatible precirol in attenuation of doxorubicin dose-dependent behavior in HUH-7 hepatocarcinoma cell line","volume":"72","author":"Tupal","year":"2020","journal-title":"Nutr Cancer"},{"issue":"Supp 1","key":"R19-20240830","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/21691401.2017.1423493","article-title":"Improved anticancer effects of epigallocatechin gallate using RGD-containing nanostructured lipid carriers","volume":"46","author":"Hajipour","year":"2018","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"R20-20240830","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ijpharm.2004.07.019","article-title":"The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs","volume":"284","author":"Kipp","year":"2004","journal-title":"Int J Pharm"},{"key":"R21-20240830","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jsps.2010.07.003","article-title":"Effect of formulation design and freeze-drying on properties of fluconazole multilamellar liposomes","volume":"18","author":"Ola","year":"2010","journal-title":"Saudi Pharm J"},{"key":"R23-20240830","first-page":"5403","article-title":"Enhanced antifungal effects of amphotericin B-TPGS-b-(PCL-ran-PGA) nanoparticles in vitro and in vivo","volume":"9","author":"Tang","year":"2014","journal-title":"Int J Nanomed"},{"key":"R24-20240830","first-page":"283","article-title":"Long-circulating and target-specific nanoparticles: Theory to practice","volume":"53","author":"Moghimi","year":"2001","journal-title":"Pharmacol Rev"},{"key":"R25-20240830","doi-asserted-by":"crossref","first-page":"44","DOI":"10.18869\/acadpub.pbr.2.1.44","article-title":"Encapsulation of nystatin in nanoliposomal formulation: characterization, stability study and antifungal activity against Candida albicans","volume":"2","author":"Saadat","year":"2016","journal-title":"Pharm Biomed Res"},{"key":"R26-20240830","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s100960000334","article-title":"In vitro activity of a new liposomal nystatin formulation against opportunistic fungal pathogens","volume":"19","author":"Quind\u00f3s","year":"2000","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R27-20240830","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1128\/AAC.43.5.1264","article-title":"Comparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole","volume":"43","author":"Oakley","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"R28-20240830","first-page":"13","article-title":"A nanoscale polynucleotide-neutral liposome self-assemblies formulated for therapeutic gene delivery","volume":"2","author":"S\u00fcleymanoglu","year":"2004","journal-title":"Electron J Biomed"}],"container-title":["Advanced Biomedical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/abr.abr_65_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:59:37Z","timestamp":1787839177000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/abr.abr_65_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/abr.abr_65_23","relation":{},"ISSN":["2277-9175"],"issn-type":[{"value":"2277-9175","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"2023-02-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}